InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Announces Participation at Upcoming Stifel 2024 Virtual CNS Days
March 11, 2024
Vistagen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, will be featured at the upcoming Stifel 2024 Virtual CNS Days. The two-day online event is scheduled for March 19–20, 2024. During the event, Vistagen CEO Shawn Singh will present, and company management will […]
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at TD Cowen Conference
February 28, 2024
Vistagen (NASDAQ: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings at the TD Cowen 44th Annual Health Care Conference. The event is taking place from March 4 to 6, 2024, in Boston, Massachusetts. Vistagen […]
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Releases Q3 2024 Financial Report, Corporate Update
February 14, 2024
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, is reporting its Q3 2024 financial numbers as well as providing an update on the company. Notable numbers from the report include research and development expenses reaching $4.5 million and $6.9 million for the three […]
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q3 Results, Conference Call
February 6, 2024
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast to report results for its fiscal year 2024 third quarter ended Dec. 31, 2023, and provide a corporate update. The call will begin at 2:00 p.m. […]
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) AV-101 to Receive Patent from EPO to Treat Neuropathic Pain
December 27, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received a notice of intention to grant a patent from the European Patent Office (“EPO”). The notice is regarding the use of AV-101, the company’s investigational […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2024 Financial Report, Corporate Update
November 10, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting its second-quarter 2024 results for the period ended Sept. 30, 2023. Highlights of the report include that fasedienol (“PH94B”), the company’s PALISADE phase 3 program […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Plans to Present Positive Study Results at Conferences in November
November 7, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will be presenting at two scientific conferences in November: the CNS Summit 2023 and the 2023 Neuroscience Education Institute (“NEI”) Congress. According to the announcement, positive top-line […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q2 Results, Corporate Update Conference Call
November 6, 2023
Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company has announced that it will host a conference call and webcast at 2:00 p.m. Pacific Time on Thursday, Nov. 9, 2023, to provide a corporate […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Inaugural Biotech CNS/Neuro Summit
October 5, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will be presenting at the upcoming Jefferies Biotech CNS/Neuro Summit. Held for the first time, the summit is scheduled for Oct. 11–12, 2023, in New York City. […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Pricing of $100M Underwritten Offering
October 2, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced the pricing of a $100 million underwritten offering of its common stock (or pre-funded warrants to purchase common stock) and warrants to purchase common stock (or […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Reports on Phase 2A Study Results Regarding Treatment of Premenstrual Dysphoric Disorder
September 12, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting on study results for PH80, one of its five investigational neuroactive nasal sprays. According to the announcement, PH80 exhibited statistically significant improvement versus placebo in […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), Fuji Pharma Co. Ltd. (TSE: 4554) Announce Exclusive Negotiation Agreement
September 5, 2023
Vistagen (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. Together with Fuji Pharma Co. (TSE: 4554), a pharmaceutical company specializing in development, manufacture and marketing in the fields of women’s health care and acute medical care, the […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Appoints Highly Accomplished Finance Professional as CFO
August 22, 2023
Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced its appointment of Cindy Anderson as chief financial officer (“CFO”), effective Aug. 21, 2023. Anderson succeeds Jerrold Dotson, whose planned retirement was announced […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2024 Financial Report, Corporate Update
August 11, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting its financial results for the first quarter of 2024, the period ending June 30, 2023; the company also released a corporate update. Highlights of the […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2024 Numbers, Corporate Update Conference Call
August 9, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced plans to report its Q1 2024 financial results. In conjunction with that, the company will also host a corporate conference call. According to the announcement, […]
InvestorNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Fasedienol Demonstrates Potential to Transform Treatment Landscape for Social Anxiety Disorder
August 7, 2023
Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced positive top-line results from its Phase 3 PALISADE-2 trial. The trial, to evaluate the efficacy, safety and tolerability of fasedienol (“PH94B”) nasal spray in adults diagnosed with […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces New Preclinical Data Further Demonstrating Unique Mechanism of Action for Itruvone (‘PH10’)
July 17, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced new mechanism of action data from a preclinical tissue distribution study in laboratory rats. According to the update, the study demonstrated that a single intranasal administration […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Receipt from CIPO of Notice of Allowance for Dyskinesia Treatment
July 14, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received a Notice of Allowance from the Canadian Intellectual Property Office (“CIPO”) for a patent related to AV-101. AV-101 is the company’s oral prodrug antagonist at […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2023 Financial Report, Corporate Update
June 29, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is releasing its 2023 fiscal year report. Highlights of the report include positive results reported in the company’s phase 3 open label study of fasedienol (“PH94B”) in […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Scheduled Conference Call to Report on FY 2023 Financial Numbers
June 28, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will host a conference call and webcast today at 1:30 p.m. PT (4:30 p.m. ET). The company scheduled the event to report results for its fiscal year […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Regains Compliance with Nasdaq Listing Requirements
June 23, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced its June 22, 2023, receipt of a letter from the listing qualifications staff of the Nasdaq Stock Market LLC. The letter indicates that Vistagen has regained […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Eyes Advancement of Itruvone into Phase 2B Development
June 21, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced favorable safety and tolerability data from its U.S. phase 1 clinical trial of itruvone. “PH10” is the company’s investigational rapid-onset pherine nasal spray for the treatment […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Upcoming Maxim Group Healthcare Virtual Conference
June 16, 2023
Vistagen Therapeutics (NASDAQ: VTGN) CEO Shawn Singh will participate in this month’s Healthcare Virtual Conference presented by Maxim Group LLC. The three-day online event is scheduled for June 20–22, 2023, and will be hosted on the M-Vest platform. Vistagen is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) PH80 Nasal Spray to Receive EPO Patent Approval
June 13, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received notification that the European Patent Office (“EPO”) intends to grant its patent application for PH80 nasal spray. According to the announcement, the EPO issued an […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Results from PH80 Exploratory Phase 2A Study
June 8, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced that PH80, one of the company’s five investigational neuroactive nasal sprays, demonstrated statistically significant efficacy versus placebo in an exploratory phase 2A study. The randomized, double-blind, […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Participate in Upcoming Jefferies Global Healthcare Conference
June 7, 2023
Vistagen Therapeutics (NASDAQ: VTGN) CEO Shawn Singh will be presenting at the 2023 Jefferies Global Healthcare Conference. Vistagen is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. According to the announcement, the conference is scheduled for June 7–9, 2023, […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Implement Board-Approved Reverse Stock Split
June 6, 2023
Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common stock, at a ratio of one-for-thirty, as unanimously […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Presents Phase 3 SAD Study Results at ASCP Annual Meeting
June 1, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has reported the results of its phase 3 open-label study of fasedienol (“PH94B”) nasal spray for the treatment of adults with social anxiety disorder (“SAD”). The company […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Report Phase 3 Study Results at Upcoming ASCP Annual Meeting
May 31, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, announced that it will be sharing the results of its phase 3 open-label study of fasedienol (“PH94B”) nasal spray for the treatment of adults with social anxiety […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Recognized with MHA Platinum Bell Seal for Workplace Mental Health
May 24, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has been recognized by Mental Health America (“MHA”) for its commitment to fostering mental health and well-being in the workplace. According to the announcement, the company earned […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Portfolio with New European Patent for AV-101
April 6, 2023
Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that the European Patent Office (“EPO”) has granted a patent for AV-101, Vistagen’s oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist. “Expanding our patent […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Receives Positive FDA Feedback Regarding Use of LSAS in Planned Phase 3 Study
March 30, 2023
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting positive feedback from the U.S. Food and Drug Administration (“FDA”). The feedback is in relation to the company’s use of the Liebowitz Social Anxiety Scale […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Results from PH94B Phase 3 Study
March 22, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced positive data from its phase 3 open-label study. According to the update, the study is designed to evaluate the safety and tolerability of multiple, as-needed intranasal […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Provides Update on Phase 1 Clinical Trial of Proprietary PH10
March 9, 2023
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced key updates regarding its phase 1 clinical trial of itruvone (“PH10”). The company reported that the last participant in the trial has completed the study […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Upcoming Health Care Conference
March 2, 2023
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will be presenting at the 43rd annual Cowen Health Care Conference. The three-day event is scheduled for March 6–8, 2023, in Boston. VistaGen CEO Shawn Singh will […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Secures US Patent for PH80 Nasal Spray for Treatment of Migraine
March 1, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted a U.S. patent for Vistagen’s PH80 nasal spray for the treatment of migraine. According to the […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2023 Financial Results, Corporate Update
February 8, 2023
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting on its fiscal year 2023 third quarter ended December 31, 2022; the report also included corporate highlights for the same period. According to the report, […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q3 Fiscal 2023 Results Call and Webcast
February 6, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced that it will host a conference call and webcast at 2:00 p.m. PT/5:00 p.m. ET on Tuesday, Feb. 7, 2023. At that time, Vistagen will report […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Closing of Strategic Acquisition
February 2, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced the closing of its acquisition of Pherin Pharmaceuticals Inc., a privately held drug development company focused on neuropsychiatric and neuroendocrine conditions. Vistagen now owns all intellectual […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Doses First Participants in PH10 Phase 1 Clinical Trial
January 24, 2023
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, announced that the first cohort of healthy volunteers has been dosed in its U.S. phase 1 clinical trial of PH10. The trial includes a newly optimized formulation […]